CYCN: Cyclerion Therapeutics, Inc.
About
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Current Value
$1.781 Year Return
Current Value
$1.781 Year Return
Key Details
Market Cap
$4.77M
P/E Ratio
-0.83
1Y Stock Return
-16.19%
1Y Revenue Growth
-68.09%
Dividend Yield
0.00%
Price to Book
0.5
Strategies that include CYCN
Stock's related to CYCN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SEI | 30.04% | $616.12M | +133.06% | 2.39% |
| TEM | 24.25% | $8.50B | 0.00% | 0.00% |
| HE | 21.59% | $1.82B | -17.47% | 0.00% |
| JRVR | 20.95% | $168.34M | -52.25% | 4.52% |
| FENG | 20.34% | $13.37M | +96.77% | 0.00% |
| UL | 19.86% | $143.25B | +21.40% | 3.25% |
| AEHR | 19.40% | $330.68M | -56.08% | 0.00% |
| MUSA | 19.19% | $10.62B | +42.37% | 0.34% |
| CMBM | 18.84% | $30.22M | -75.23% | 0.00% |
| CP | 18.75% | $68.86B | +3.97% | 0.76% |
| BTI | 18.66% | $81.54B | +16.13% | 8.08% |
| PENG | 17.73% | $911.79M | +4.97% | 0.00% |
| QURE | 17.43% | $283.68M | -13.52% | 0.00% |
| CSGS | 17.34% | $1.58B | +5.75% | 2.18% |
| OHI | 16.90% | $10.84B | +26.02% | 6.71% |
| SGML | 16.80% | $1.54B | -51.62% | 0.00% |
| LNTH | 16.61% | $5.52B | +16.60% | 0.00% |
| MCD | 16.36% | $208.34B | +3.66% | 2.30% |
| FF | 15.99% | $227.57M | +21.57% | 4.55% |
| TIMB | 15.91% | $6.86B | -17.12% | 4.05% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| WOR | -0.01% | $1.94B | -5.56% | 1.27% |
| UPLD | 0.01% | $87.26M | -26.39% | 0.00% |
| ATEX | -0.01% | $617.94M | +5.94% | 0.00% |
| MKSI | 0.01% | $7.29B | +42.89% | 0.82% |
| INDB | -0.01% | $3.00B | +28.34% | 3.21% |
| RUN | 0.02% | $2.18B | -16.08% | 0.00% |
| MSGE | 0.02% | $1.72B | +17.13% | 0.00% |
| CSTL | 0.02% | $808.57M | +48.97% | 0.00% |
| HTGC | -0.02% | - | - | 8.42% |
| AES | -0.02% | $9.78B | -17.86% | 5.04% |
| ATMU | 0.02% | $3.57B | +98.98% | 0.23% |
| MYGN | 0.02% | $1.37B | -14.19% | 0.00% |
| JBI | -0.03% | $1.00B | -31.76% | 0.00% |
| SYPR | -0.03% | $32.23M | -26.32% | 0.00% |
| RPM | -0.03% | $17.37B | +32.07% | 1.41% |
| AMRK | -0.03% | $697.61M | +7.29% | 2.67% |
| BTBT | 0.04% | $595.60M | +81.53% | 0.00% |
| GUG | -0.04% | - | - | 9.13% |
| SWTX | -0.04% | $2.82B | +79.34% | 0.00% |
| AKRO | -0.04% | $2.17B | +93.09% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LZ | -24.71% | $1.30B | -33.57% | 0.00% |
| LQDT | -21.35% | $774.00M | +22.17% | 0.00% |
| CEPU | -20.49% | $2.07B | +87.28% | 0.00% |
| FUN | -19.40% | $4.60B | -16.51% | 0.00% |
| FTAI | -18.23% | $17.54B | +308.36% | 0.70% |
| LSPD | -17.19% | $2.68B | +7.42% | 0.00% |
| AL | -16.92% | $5.37B | +25.70% | 1.74% |
| TGT | -16.75% | $71.87B | +19.27% | 2.59% |
| CPAY | -16.40% | $25.67B | +58.31% | 0.00% |
| AOSL | -16.19% | $933.92M | +47.50% | 0.00% |
| GTES | -15.97% | $5.42B | +75.43% | 0.00% |
| FOXA | -15.96% | $20.90B | +50.97% | 1.16% |
| OMC | -15.81% | $19.13B | +24.62% | 2.87% |
| BTCT | -15.21% | $42.61M | +353.33% | 0.00% |
| GBX | -15.20% | $2.03B | +73.41% | 1.86% |
| TRN | -14.51% | $3.12B | +54.58% | 2.95% |
| FOX | -14.50% | $19.74B | +52.74% | 1.23% |
| TGS | -14.07% | $1.97B | +116.04% | 0.00% |
| CMTL | -13.51% | $84.44M | -76.16% | 0.00% |
| VCEL | -13.50% | $2.76B | +55.60% | 0.00% |
ETF's related to CYCN
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.